Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  De Laurentiis, M ^a   Cancello, G ^a   Zinno, L ^a   Montagna, E ^a   Malorni, L ^a   Esposito, A ^a   Pennacchio, R ^a   Silvestro, L ^a   Giuliano, M ^a   Giordano, A ^a   Caputo, F ^a   Accurso, A ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Breast cancer; HER2; Targeted therapy; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LETROZOLE; MEMBRANE PROTEIN; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; GENE OVEREXPRESSION; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LICENSING; METASTASIS; MONOTHERAPY; NAUSEA; ONCOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY OF LIFE;

ANIMALS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; RECEPTOR, ERBB-2; TAMOXIFEN; TAXOIDS;

EID: 23844512539     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi901     Document Type: Article

References (51)

1. King CR, Kraus MH, Aaronson SA. Amplification of a novel V-ErbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
2. Ross JS, Fletcher JA. The HER-2/Neu oncogene, in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 1998; 16: 413-428.
3. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9: 1039-1046.
4. Piccart MJ, Di Leo A, Hamilton A. HER2. A 'Predictive Factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 2000; 36: 1755-1761.
5. De Placido S, Carlomagno C, De Laurentiis M, Bianco ARC-ErbB2. expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 1998; 52: 55-64.
6. De Laurentiis M, Arpino G, Massarelli E et al. HER2 as a predictive marker of resistance to endocrine treatment (ET) for advanced breast cancer (ABC): A meta-analysis of published studies. Breast Cancer Res Treat 2002; 76 (Suppl 1): (Abstr 233).
7. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/Neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-2251.
8. Kunisue H, Kurebayashi J, Otsuki T et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000; 82: 46-51.
9. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994; 64: 127-154.
10. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/Neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-2831.
11. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000; 27 (Suppl 11): 21-25.
12. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in Patients With HER2/ Neu-Overexpressing Metastatic Breast Cancer. Semin Oncol 1999; 26 (Suppl 12): 78-83.
13. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
14. Vogel CL, Cobleigh M, Tripathy D et al. Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)-selected patients. Proc Am Soc Clin Oncol 2001; 20 (Abstr 86, poster update).
15. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
16. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
17. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-3113.
18. Extra JM et al. Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first line treatment of HER2- positive metastatic breast cancer (MBC): Results of a randomised multicentre trial. Eur J Cancer 2004; 2 (Suppl. 3): 125 (Abstr 239).
19. Robert NJ, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival. Proc Am Soc Clin Oncol 2004; 23 (Abstr 573).
20. Untch M, Eidtmann H, Du Bois A et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur J Cancer 2004; 40: 988-997.
21. Theodoulou M, Campos S, Batist G et al. TLC D-99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002; 21(55a): (Abstr 216; poster update).
22. Cortes J, Climent M, Lluch A et al. Updated results of a phase II study (M77035) of myocet combined with weekly Herceptin and paclitaxel in patients with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC). Breast Cancer Res Treat 2005; 88 (Suppl. 1): (Abstr 3041).
23. Chia SK, Clemons M, Martin LA et al. A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER2 overexpressing metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004; 23: (Abstract 630; poster update).
24. Wolff AC, Wang M, Sparano JA et al. Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without tastuzumab (H) as first line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) Trial E3198. Breast Cancer Res Treat 2004; 88 (Suppl 1) (Abstr 3040).
25. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Cancer Res 2003; 9: (1 pt2); 447S-454S.
26. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
27. Wong ZW, Isaacs C, Harris L, Ellis MJ. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2003; (Abstr 444).
28. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
29. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-58.
30. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003; 4: 120-125.
31. Baselga J, Gianni L, Geyer C et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004; 31 (Suppl 10): 51-57.
32. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, Paclitaxel and Epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; published on line ahead of print, February 28, 2005.
33. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study. Anticancer Res 2001; 21: 1301-1305.
34. Uber KA, Nicholson BP, Thor A. A phase II trial of weekly Docetaxel (D) and Herceptin (H) as first or second line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20.
35. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
36. Kuzur ME, Albain KS, Huntington MO et al. A phase II trial of docetaxel and Herceptin in metastatic breast cancer overexpressing HER2. Proc Am Soc Clin Oncol 2000; 19: 148a.
37. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595.
38. Montemurro F, Choa G, Faggiuolo R et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004; 66: 38-45.
39. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004; 22: 1071-1077.
40. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26(Suppl 12): 89-95.
41. Nabholtz JM, Pienkowsky T, Patel R, Loret C, Slamon D. Results of two open label multicenter phase II pilot studies (BCIRG 101 and 102) with trastuzumab (Herceptin®) in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women over-expressing the HER2-Neu proto-oncogene. Eur J Cancer 2001; 37S: 190 (Abstr 695).
42. Slamon D, Yeon CH, Pienkowski T et al. Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with Docetaxel (T) and Platinums (C, Cisplatin or Carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). Proc Am Soc Clin Oncol 2004; 23: (Abstr 164).
43. Bangemann N, Kuhle H, Ebert A. Capecitabine Combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (NBC). Ann Oncol 2000; 11 (Suppl 4): 143.
44. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2- overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
45. De Wit M. Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine and trastuzumab in patients with HER2- positive metastatic breast cancer. Harbeck N, Thomssen C. Proc Am Soc Clin Oncol 2004; 22: 831 (Abstr 831).
46. Bayo J, Majordomo JI, Sanchez- Rovira P et al. Trastuzumab and vinorelbine combination in the treatment of HER2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22: (Abstr 763).
47. Bernardo G, Palumbo R, Bernardo A et al. Final result of a phase II study of weekly trastuzumab and vinorelbine in chemo-naive patients with HER2 overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22 (Suppl 15): (Abstr 731).
48. Jahanzeb M, Mortimer JE, Yunus F et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7: 410-417.
49. Yardley DA, Greco FA, Porter LL et al. First line treatment with weekly Docetaxel, vinorelbine and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004; 23: (Abstr 643).
50. O'Shaughnessy J, Vukelja SJ, Marsland T et al. Phase II trial of Gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: Preliminary Results. Clin Breast Cancer 2002; 3 (Suppl 1): 17-20.
51. Polyzos A, Mavroudis D, Boukovinas J et al. A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. Proc Am Soc Clin Oncol 2004; 23: (Abstr 728).